Form D · Biotechnology

Vesalius Longevity Labs (SPV) Inc.

Vancouver, A1 · CIK 0002056924

Offering snapshot reported Mar 19, 2026 · SEC filing

Reported sold
$6.71M
Offering amount: $6.71M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 11, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 19, 2026Initial$6,712,500No comparison19SEC filing
May 13, 2025Initial$250,000No comparison1SEC filing
Mar 27, 2025Initial$895,000No comparison6SEC filing
Feb 19, 2025Initial$1,700,000No comparison6SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-577064
Total Offering Amount equals the price of an aggregate of 4,625,000 shares and 8,800,000 Subscription Receipts at $0.50 per share. Each Subscription Receipt entitles the holder to acquire shares for no additional consideration subject to certain events.

Source: Form D, filed Mar 19, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Shannon Anderson Director, Promoter
Robert D Mc Cue Director, Executive
Christina Phalen Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1500 1055 West Georgia Street
Vancouver, A1, V6E 4N7